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Background: The genetic mechanisms that lead to head and neck squamous cell carcinoma 
(HNSCC) are incompletely understood.  Cancer predisposition is associated with chromosome 
instability and hypersensitivity to DNA damaging agents.  Fanconi anemia patients are extremely 
sensitive to crosslinking agents and are at increased risk of developing several cancers including 
leukemias, gynecological, and head and neck cancers.  The Fanconi Anemia proteins (FANCs) 
are involved in pathways necessary for crosslink damage recognition and repair.  Eight FANC 
proteins (A/B/C/F/G/I/J/L) assemble into a nuclear complex and two other proteins, 
FANCD1/BRCA2 and FANCD2 act downstream of the core complex. This FA protein complex 
is required for the monoubiquitination of the FANCD2 protein in response to DNA damage.  By 
testing head and neck tumors for FANC characteristics, such as hypersensitivity to DNA 
crosslinking agents, increased chromosome breakage FANCD2 protein ubiquitination, formation 
of radial figures and genomic instability, we can determine whether this specific DNA damage 
repair pathway is intact in the tumors.  
 Methods:  Head and neck tumor cell lines were treated with the clastogenic crosslinking agent, 
diepoxybutane (DEB), and double-strand breaks and chromosomal aberrations were quantified.  
FANCA and FANCD2 cell lines were analyzed as positive controls and normal peripheral blood 
lymphocytes were used as negative controls. 
 iv
Findings: HNSCC cell lines treated with DEB have an increased number of DEB-induced 
double-strand breaks compared to normal lymphocytes, as evidenced by increased chromosomal 
breaks and tri- and quadriradials, suggesting defects in the DNA damage response.   
 Interpretation:  Patients who are hypersensitive to DNA damage are at increased risk of 
developing several types of cancer at an early age.  Likewise, we predicted and showed that head 
and neck tumors have defects in the FANC pathway. This might suggest that the genes in the 
pathway either had germline or acquired alterations (mutations or regulatory defects), which 
could be tested by comparing normal cells from these patients to the tumor cells. Identifying and 
examining the mechanisms by which DNA damage occurs and is repaired can lead to a better 
understanding of genetic predisposition to cancer and to advances in early detection and 
treatment, therefore reducing morbidity and mortality.   
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1. Introduction 
Head and neck cancer 
1.1.1. Overview 
Cancer is a disease that is caused when regulatory mechanisms that limit cell division are 
defective and cells undergo unregulated division while normal cell growth and behavior is lost 
(46).  The cell cycle is a highly regulated process that results in cell growth and division into two 
daughter cells.  The cell cycle has four stages: G1; growth and development of the cell, S; DNA 
synthesis leading to chromosome replication, G2- growth and development, M; mitosis, during 
which chromosomes are divided between two daughter cells.  Normally, the cell cycle is 
regulated by many signals, including external growth factors, which are proteins that are required 
to stimulate cell division.  When cells lose their dependence on growth factors, but divide 
without stimulation, this can lead to cancer (20).   
 Head and neck cancer accounts for about 3% of all cancers.   Specifically, in 2005, the 
American Cancer Society estimates that there will be approximately 10,000 new cases of 
laryngeal cancer and 29,000 new cases of oral cavity cancer with approximately 4,000 and 7,000 
deaths, respectively (3).   This type of cancer usually affects individuals over 50 years of age and 
affects twice as many males as females.  Most tumors of the head and neck are squamous cell 
carcinomas, which are characterized by thin, flat cells.  Cancers of the head and neck are further 
characterized by the area of the body in which they begin.  These include the oral cavity, 
pharynx, larynx, and the salivary glands. 
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  The most significant risk factors for head and neck cancer are tobacco (including 
smokeless tobacco) and alcohol use. Eighty-five percent of head and neck cancers are linked to 
tobacco use. People who use both tobacco and alcohol are at even greater risk for developing 
these cancers than people who use either tobacco or alcohol alone.   Other risk factors include 
poor dental hygiene, environmental exposures such as inhalation of asbestos, radiation exposure, 
and viruses, such as HPV (human papillomavirus) and Epstein-Barr (38).   
 Symptoms that are common in head and neck cancer include lump or sore that does not 
heal, a sore throat that does not go away, difficulty swallowing, and/or a change or hoarseness in 
the voice.  Patients are referred to a specialist, such as an Otolaryngologist after general 
Physicians or Dentists suspect head and neck cancer in individuals with these symptoms.  The 
Otolaryngologist can confirm the diagnosis by a physical exam with laryngoscope to look inside 
the throat, MRI and/or CT scans, and a biopsy of the suspected cancerous tissue (30). 
Treatment of head and neck cancer depends on the location and size of the tumor, and the 
patient’s general health.  Generally, surgery is performed to remove the cancerous tissue and 
radiation treatment and/or chemotherapy may be recommended, depending on the stage of the 
cancer (10).  Prognosis also depends on the stage of the cancer.  Survival rates after diagnosis of 
head and neck cancer are: 1 year-85%, 5 year: 58%, and 10 year: 48%.  A recurrence is most 
likely to occur in two to three years after the original diagnosis (3).    
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1.1.2. Genetics of head and neck cancer 
Head and neck cancer is not considered a hereditary cancer.  This means that a 
predisposition for this type of cancer is not thought to be inherited from generation to generation. 
Instead, it occurs as a result of environmental exposures that can cause many genetic mutation 
events over time.  The exact mechanisms that lead to malignancy in cells are unknown.  
Mutation(s) in any of the genes that maintain DNA fidelity though replication, repair, 
chromosome segregation and apoptosis may be responsible for tumor formation and 
development of cancer (22).  Cells have several different mechanisms to protect against 
replication of abnormal cells, including cell cycle checkpoints, insurance of proper chromosome 
segregation, telomere maintenance, and the DNA damage response. Many different genes encode 
proteins that are involved in pathways that regulate cell growth, function and death (summarized 
in Table 1, modified from (12)).  Certain individuals may have inherited genetic susceptibility to 
cancer development through defects in DNA damage repair pathways.  Research suggests that 
many of these pathways may be interconnected.    
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Table 1: A selection of genes, defective expression of which leads to chromosome instability 
Modified from Gollin, 2005 (12) 
 
Gene name Descriptive name Implicated in 
 AURKA Aurora kinase A Chromosome segregation defects 
 AURKB Aurora kinase B Chromosome segregation defects 
 BUB1 Budding uninhibited by benzimidazoles 1 homolog 
Chromosome segregation 
defects 
 BUB1B/BUBR1 Budding uninhibited by benzimidazoles 1 homolog beta 
Chromosome segregation 
defects 
 FLJ10036 Zwilch (Drosophila) Chromosome segregation defects 
 KNTC1 Kinetochore-associated 1; alias Rod 
Chromosome segregation 
defects 
 MAD2L1 MAD2 Mitotic arrest deficient-like 1 (yeast) 
Chromosome segregation 
defects 
 ZW10 
ZW10 homolog 
centromere/kinetochore protein 
(Drosophila) 
Chromosome segregation 
defects 
 ATM Ataxia telangiectasia mutated DNA damage response defects 
 ATR Ataxia telangiectasia and Rad3 related 
DNA damage response defects 
 BARD1 BRCA1 associated RING domain 1 DNA damage response defects 
 BLM Bloom syndrome gene DNA damage response defects 
 BRCA2 Breast cancer 2, early onset; aliases FANCD1, FANCB 
DNA damage response defects 
 FANCA-L Fanconi anemia genes A-L DNA damage response defects 
 H2AFX H2A histone family member X, H2AX 
DNA damage response defects 
 MRE11A MRE11 meiotic recombination 11 homolog A (S. cerevisiae) 
DNA damage response defects 
 NBS1 Nijmegen breakage syndrome 1; nibrin 
DNA damage response defects 
 POLB DNA polymerase beta DNA damage response defects 
TP53  DNA damage response defects 
 PINX1 PIN2-interacting protein 1 Telomere dysfunction 
 TERC Telomerase RNA component Telomere dysfunction 
 TERF1/PIN2 
Telomeric repeat binding factor 
(NIMA interacting) 1; aliases 
PIN2, TRF, TRF1 
Telomere dysfunction 
 CCNE1 Cyclin E Telomere dysfunction 
 CDC4/FBXW7 
F-box and WD-40 domain protein 
7, archipeligo homolog 
(Drosophila) 
Telomere dysfunction 
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 There are five major DNA damage repair pathways: homologous recombination repair (HR), 
non-homologous end-joining (NHEJ), nucleotide excision repair (NER), base excision repair 
(BER), and mismatch repair (MMR) (6).  In HR, sequence information that is lost due to damage 
in one double-stranded DNA molecule is accurately replaced by physical exchange of a segment 
from an intact homologous DNA molecule.  (33).  NHEJ also repairs double-strand breaks, by 
bringing broken DNA ends together and directly ligating the ends back together (7).  This can 
result in the loss of some genetic material, i.e., the creation of deletion mutation.  It is thought 
that cells repair the majority of double-strand breaks by NHEJ, although there is evidence that 
NHEJ may be coupled to HRR to generate accurate repair of double-strand breaks (31).  NER 
repairs DNA with helix-distorting damage, including cyclobutane pyrimidine dimers and 6–4 
photoproducts produced by UV light, and adducts produced by the chemotherapeutic agents, 
cisplatin and 4-nitroquinoline oxide (15).  BER is a major DNA repair pathway protecting 
mammalian cells against single-base DNA damage (6).  MMR proteins are primarily responsible 
for the post-replication correction of nucleotide mispairs and extra-helical loops. Mutational 
defects in MMR genes give rise to a mutator phenotype, microsatellite instability, and a 
predisposition to cancer. MMR mutations are implicated in the etiology of hereditary non-
polyposis colorectal cancer (HNPCC) syndrome and a wide variety of other sporadic tumors 
(25).   
  Research shows that cancer cells commonly exhibit chromosomal instability and this 
instability is apparent in tumors of the oral cavity and the head and neck region (34).  
Chromosomal instability is the occurrence of gains and/or losses of whole chromosomes or 
chromosome segments which occur at increased rate than would be expected in a normal cell 
population (16).  Chromosomal instability is thought to be the means by which normal cells 
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 develop the features that enable them to become cancer cells (16). Cells are constantly exposed 
to DNA damaging agents, but have elaborate and highly conserved pathways to sense, signal, 
and repair this damage, therefore maintaining genomic stability (48).  In addition to the DNA 
damage repair pathways previously described, there are signal transduction pathways triggered 
by DNA damage checkpoints.  Through these pathways, damage is recognized and the cell cycle 
progression is delayed to allow DNA damage to be repaired before replication or cell division 
takes place. Unrepaired double-strand breaks cause chromosomal aberrations, which in turn lead 
to dysregulation of cell cycle control genes and further genomic instability in cells, eventually 
leading to tumorigenesis (19).   Signaling of DNA DSBs to delay the cell cycle for repair seems 
to occur mainly through the checkpoint kinases, ATM (Ataxia telangiectasia mutated) and ATR 
(Ataxia telangiectasia Rad-3 related protein). Another kinase, DNA-PK is also a key player in 
the recognition of a DNA lesion (40).    ATM and ATR are activated in response to a double-
strand break and in turn phosphorylate other proteins involved HRR and NHEJ to prevent cell 
cycle progression and coordinate repair of the break. 
Deleterious mutations in genes encoding proteins employed in DNA repair and/or 
apoptosis (e.g. TP53) increase genomic instability. Genomic instability increases the occurrence 
of new mutations, including those affecting oncogenes and tumor suppressor genes. It is thought 
that genomic instability drives tumor progression.  The exact relationship between the DNA 
damage response and how it leads to chromosomal instability in unknown, however 
haploinsufficiency for critical DNA damage response may be important for tumorigenesis (11). 
Chromosomal instability in head and neck and oral cancers has been associated with 
amplification of chromosome band 11q13  (13).  Approximately 45% of head and neck and oral 
squamous cell carcinomas exhibit this DNA amplification that results in upregulation and 
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 overexpression of genes in this region. Research has shown that Breakage-fusion-bridge (BFB) 
cycles may lead to gene amplification (35;39)   The mechanism by which amplification occurs 
by BFB cycles has been described and is thought to propagate chromosomal instability (26).  As 
a consequence of chromosome breakage, it is thought that sister chromatids fuse following 
replication, giving rise to dicentric chromosomes.  At anaphase, the dicentric chromosome may 
be pulled to opposite poles resulting in breakage.  Figure 1 shows how this cycle repeats and 
results in an amplified chromosomal region, therefore chromosomal instability.   
 
 
         1.                 2.              3.         4.  
 
          
 
 
 
 
 
 
 
Figure 1: Schematic of breakage fusion bridge cycle 
This figure shows the proposed mechanism of chromosomal amplification via breakage fusion 
bridge cycles.  1.  A chromosome break occurs 2. sister chromatids fuse  3.  Formation of a 
dicentric chromosome 4. Dicentric chromosome breaks and cycle repeats itself.  Adapted from 
Gollin, SM and Reshmi, SC, unpublished. 
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 Chromosomal breakage, via BFB, at or near chromosomal band 11q13 has been shown to 
result in loss of the distal segment of chromosome 11 (18).  Within this region, there are genes 
critical for proper DNA damage repair including: MRE11A (11q21), H2AFX (11q22.3), ATM 
(11q23.2-q23.3) and CHEK1 (11q24).  As previously discussed, ATM is a significant part of 
cellular response to DNA damage, specifically DSBs. ATM protein responds to DNA damage 
and phosphorylates more than 15 known substrates from the DNA damage response genes 
including: TP53, BRCA1, FANC, BLM, CHEK2, and MRE11, which are associated with familial 
cancer syndromes (36). CHEK1 also works to delay cell cycle progression when double-strand 
breaks are present.  It is regulated by ATR and is required for the G2/M damage checkpoint (24). 
MRE11 is required for DSB repair via HRR and possibly also NHEJ.  It functions in the 
RAD50/MRE11/NBS complex which interacts with BRCA1 in repair (47).  H2AX is also 
involved in DNA DSB repair.  It is phosphorylated by ATM, ATR and DNA-PK and interacts 
with BRCA1, BRCA2, and the RAD50/MRE11/NBS complex (45).  Thus loss of any of the 
genes in 11q23.2-q23.3, leading to haploinsufficiency, may result in dysregulation of the DNA 
damage response and further genomic instability. 
   Amplification of 11q13 itself is associated with poor prognosis (4).   Haploinsuficiency 
of critical DNA damage response genes in the distal 11q region are thought to result in a sluggish 
DNA damage response (14).  Other substrates from other DNA damage repair proteins 
downstream of ATM and previously mentioned proteins may have a similar response.  
Specifically, ATM phosphorylates FANC (Fanconi anemia) proteins.  Individuals with the 
inherited disease, Fanconi Anemia have a 500-fold increased risk for head and neck cancer. 
Therefore, possible acquired mutations leading to haploinsufficiency of the FANC genes may 
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 also play a role in development of head and neck tumors.  An overview of Fanconi anemia and 
the relationship to head and neck cancer will be discussed in detail in the next sections.   
 
  
Overview of Fanconi anemia 
1.1.3. Physical characteristics of patients with Fanconi anemia 
Fanconi anemia(FA) is an inherited disorder characterized by physical abnormalities, bone 
marrow failure, and an increased risk of cancer.  This genetic disorder is inherited in an 
autosomal recessive pattern, meaning that both parents have to be carriers of a mutation in one of 
the two copies of their eleven FANC genes and both must pass that mutated allele on to their 
offspring.  In the general population, about 1/100,000 individuals are affected with Fanconi 
anemia, and 1/300 are carriers. Fanconi anemia is more common in individuals of Ashkenazi 
Jewish descent, who have a carrier frequency of approximately 1/100 (21). 
 Fanconi anemia can be difficult to diagnose due to the phenotypic variability observed in 
those affected and features that overlap with other genetic syndromes.  Early diagnosis made at 
birth or in early childhood is usually based on a collection of physical characteristics by a 
Medical Geneticist. However, approximately 25% of individuals affected with Fanconi anemia 
will not have any distinguishing physical characteristics. Clinical characteristics are summarized 
in (43). Of the 75% of patients who are dysmorphic, the most common characteristics are short 
stature (51%) and abnormal skin pigmentation (55%).  Another common feature is upper limb 
abnormalities (43%), including absent, hypoplastic, or supernumerary thumbs, clinodactyly, 
polydactyly, absent first metacarpal, short fingers, transverse crease, as well as hypoplastic or 
absent ulnae or radaii.  Individuals with FA can also have eye abnormalities (23%), which 
9 
 include microphthalmia, strabismus, prominent epicanthal folds, hypertelorism/hypotelorism, 
ptosis, slanting palpebral fissures, cataracts, epiphora, and nystagmus.  Renal anomalies (21%) 
are also observed and include, horseshoe, hypoplastic or dysplastic kidney, hydronephosis, 
hydroureter, and reflux.  Genitalia can also be abnormal, although this is much more common in 
males (32% males, 3% females).  Males with FA can have hypogenitalia, undescended, absent or 
atrophic testes, azoospermia, phimosis, delayed puberty, although a few males with FA have 
fathered children.  Females may have hypoplastic vulva, bicornuate uterus, absence of the uterus 
or vagina and ovarian atresia.  Delayed menarche, irregular menses, and early menopause are 
seen in females, although successful pregnancies resulting in liveborn children have been 
reported.  Gastroinstestinal and cardiopulmonary (11%) defects can include 
esophageal/duodenual/jejunal atresia, tracheoesophageal fistula, anteriorly placed anus, 
imperforate anus, persistent cloaca, Meckel's diverticulum, umbilical hernia, abnormal biliary 
ducts, megacolon, abdominal diastasis, Budd-Chiari syndrome, annular pancreas as well as 
structural defects of the heart and cardiomyopathy.  Some individuals with FA may also have ear 
abnormalities (9%) including hearing loss which is usually conductive secondary to middle ear 
abnormalities and structural defects which include abnormal pinna (low-set, large, or small) and 
stenosis or atresia of the external auditory meatus.  Lower limbs (8%) can also be abnormal and 
presentation may include toe syndactyly, pes planus, abnormal toes, and congenital hip 
dislocation.  Finally, other abnormalities reported in individuals affected with FA are high-
arched palate, arterial malformation, moyamoya syndrome (stenosis of blood vessels in the brain 
that causes paralysis of extremities, headaches, visual problems, and mental retardation), absent 
breast buds, absent pulmonary lobes, microcephaly, hydrocephalus, micrognathia, and vertebral 
abnormalities. 
10 
 Many cases of Fanconi anemia are identified after a diagnosis of leukemia or bone 
marrow failure (44). Bone marrow failure (BMF) usually presents in the first decade of life, but 
age of onset is variable.  BMF is a progressive decrease in peripheral blood counts, which 
includes thrombocytopenia (low blood platelet count that can cause spontaneous bleeding and 
hemorrhage), leukopenia (low count of white blood cells) and anemia (decrease in the number of 
red blood cells causing decrease in oxygen carrying capabilities of RBC resulting in fatigue, 
cardiac problems and infections).  An individual with FA may also present with myelodysplastic 
syndrome (MDS).  In childhood, MDS encompasses a diverse group of bone marrow disorders 
that share a common clonal defect in the stem cells.  These disorders are characterized by one or 
more cytopenias, despite a relatively hypercellular bone marrow.  MDS is rare in childhood, and 
most children have a rapidly progressive course with extremely poor prognosis(28).  They are 
referred to as preleukemia because of their tendency to transform into acute myelogenous 
leukemia (AML).  AML is common in individuals with FA. In fact, the risk for AML in FA 
individual is increased 785-fold (32).  AML is a malignant disease of the bone marrow in which 
hematopoietic precursors are arrested in an early stage of development.  AML is distinguished 
from other related blood disorders by the presence of more than 30% blasts in the blood and/or 
bone marrow in most AML subtypes.  Prognosis is usually poor and these children require a 
bone marrow transplant (2).  
Some individuals with FA may not be diagnosed at an early age based on absence of FA-
related physical features and/or because they “escaped” leukemia development.  These 
individuals are sometimes identified after developing certain solid tumors in their twenties or 
thirties.  The solid tumors include head and neck, genital tract, GI tract, and skin cancer.  
According to the International Fanconi Anemia Registry (IFAR), 3% of FA patients developed 
11 
 solid tumors at a young age (range 15-49 years old).  In 2003, The Surveillance, Epidemiology, 
and End Results (SEER) Program of the National Cancer Institute found that the incidence 
among this age range was 0.038%, which is significantly less than what has been observed in the 
FA population.  Those patients with FA, even after BMT, are still at increased risk of developing 
solid tumors.  Overall risks by the fourth decade in someone with FA are 90% for BMF, 10-33% 
for hematologic malignancies, 29% for other malignancies as well as inordinate toxicities from 
chemotherapy or radiation (19). Therefore, patients with Fanconi anemia are at an increased risk 
of several cancers, and should be followed closely by a physician and screened for these cancers 
accordingly.   
 
1.1.4. Testing methods for Fanconi anemia 
Genetic testing can be done to determine if an individual has Fanconi anemia.  The diagnostic 
test which is considered “the gold standard” is chromosome breakage analysis (5).  Other testing 
methods include full sequencing and mutation analysis and immunoblotting, which is done on a 
research basis at this time (37).   
Individuals affected with FA have an increased amount of double-stranded chromosome 
breaks when exposed to DEB, due to the defects in the DNA damage repair pathway. Breaks are 
quantified by breaks per chromosome. Cells with more than 1.0 average break per chromosome 
are considered to have increased breakage.  The presence of greater than 30% cells with radial 
formation is diagnostic for FA (5). Chromosome breakage is analyzed by obtaining peripheral 
blood from the suspected affected individual and culturing cells in the presence of the cross-
linking agent, DEB. Untreated cells from the patient are also cultured, but without DEB and used 
as a positive control.  Then, a total of fifty metaphase cells from lymphocytes are scored and 
analyzed for chromosomal breakage including the formation of radials, the characteristic finding 
12 
 in this disease. Results are compared to the positive control and a normal control that have been 
tested in parallel.  The normal control is a sex and age matched individual with no history of FA. 
These cells are cultured and one flask is treated with DEB and the other is left untreated. The 
cultures without the DNA clastogenic agent are used to measure the spontaneous breakage rate. 
Results are reported as either average number of breaks/cell or as x number of cells with 
1,2,3...>8 breaks.  The number of cells with radial formation is recorded.  In addition to using 
this test to confirm a diagnosis of FA, prenatal testing can be performed. This is offered for 
fetuses at 25% risk and is performed via chorionic villus sampling (CVS) or amniocentesis.  
Affected fetuses will have increased breakage in chorionic villi or amniocytes (1).   
Even though the chromosome breakage test is considered the “gold standard”, there are 
limitations.  For instance, the result may be complicated by mosaicism.  Mosaicism refers to the 
reversion of the inherited FA mutation in a subpopulation of patient’s cells.  As a result of the 
reversion, these cells are no longer sensitive to crosslinking agents and therefore appear normal 
in a chromosome breakage test, giving  a false negative DEB/MMC result.  In individuals with a 
negative DEB/MMC test in whom a high degree of clinical suspicion remains, DEB/MMC 
testing could be performed on an alternative cell type, such as skin fibroblasts, to establish the 
diagnosis. Also, this test cannot detect FA heterozygotes (carriers). 
Another method that has been used in the diagnosis and study of FA is immunodetection 
of ubiquitinated FANCD2.  FANCD2 monoubiquitination is essential for the functional integrity 
of the FA pathway as measured by resistance to MMC or DEB. Because FANCD2 
monoubiquitination is intact in other bone marrow failure syndromes and chromosomal breakage 
syndromes tested to date, evaluation of FANCD2 monoubiquitination by immunoblotting 
provides a rapid diagnostic test for Fanconi anemia. Limitations of this test include the likelihood 
13 
 that rare FA subtype FANCD1 would be missed by this approach, as could individuals with 
somatic mosaicism.  Also, this test is only available on a research basis at this time. 
Molecular genetic testing is also available.  Nine of the eleven genes in the Fanconi 
complementation group have been identified and mutation analysis is available (Table 2). 
Table 2: Summary of molecular testing in Fanconi anemia 
Complementation 
Group 
Chromosome 
Locus 
Test 
Methods 
Mutations
Detected 
Detection 
Rate 
Test 
Availability
FANCA 16q24.3 Sequence analysis Sequence Alterations 66% 
Clinical 
FANCB X Mutation analysis Sequence Alterations 0.8% 
Research 
FANCC 
9q22.3 Sequence analysis 
Sequence 
Alterations 
IVS4 +4 A 
to T 
9.6% 
Clinical 
FANCD1/BRCA2 13q12.3 Direct DNA1 Sequence Alterations 3.3% 
Research 
FANCD2 3p25.3 Direct DNA Sequence Alterations 3.3% 
Research 
FANCE 6p22-p21 Direct DNA Sequence Alterations 2.5% 
Research 
FANCF 11p15 Sequence analysis Sequence Alterations 2.1% 
Clinical 
FANCG 9p13 Sequence analysis Sequence Alterations 8.8% 
Clinical 
FANCI Unknown N/A Sequence Alterations Unknown 
Research 
FANCJ Unknown N/A Sequence Alterations Unknown 
Research 
FANCL 2p16.1 Direct DNA Sequence Alterations 0.4% 
Research 
1-Direct DNA testing may include mutation analysis, mutation scanning, sequence analysis 
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 In addition to confirming a suspected diagnosis of FA in an individual, molecular testing can also 
be used for carrier testing and prenatal diagnosis.  When using molecular testing, there are issues 
to consider regarding interpretation of results (Adapted from the ACMG Recommendations for 
Standards for Interpretation of Sequence Variations 2000).  The types of sequence alterations 
that may be detected can be reported in five categories: 
1. Pathogenic sequence alteration reported in the literature  
2. Sequence alteration predicted to be pathogenic, but not reported in the literature 
3. Unknown sequence alteration of unpredictable clinical significance   
4. Sequence alteration predicted to be benign, but not reported in the literature  
5. Benign sequence alteration reported in the literature 
 
Therefore, there can be some uncertainty when reporting results to patients due to the 
limited knowledge about FA mutations.  There are a number of possibilities to consider if a 
sequence alteration is not detected.  These include the following: the patient does not have a 
mutation in the tested gene (e.g., a sequence alteration exists in another gene at another locus), 
the patient has a sequence alteration that cannot be detected by sequence analysis (e.g., a large 
deletion, a splice site deletion), the patient has a sequence alteration in a region of the gene (e.g., 
an intron or regulatory region) not covered by the laboratory test.  There are also limitations with 
molecular testing.  Molecular testing is complicated by the number of possible associated genes 
and by the large number of possible mutations in each gene, and the large size of many of the FA 
genes.  Also, BRCA2 mutation analysis and sequencing is available clinically for hereditary 
breast/ovarian cancer; however, information is limited regarding its possible application in FA. 
1.1.5. Management of Fanconi Anemia 
A multidisciplinary approach is used to manage an individual diagnosed with FA as summarized 
in Fanconi Anemia: Standards for Clinical Care (2). The physical abnormalities can be assessed 
and monitored.  These assessments include kidney/renal ultrasound to rule out kidney 
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 abnormalities, formal hearing test, developmental assessment in young children, ophthalmology 
referral, genetics evaluation, referral to an Endocrinologist to monitor growth and development.   
There are also recommendations to manage bone marrow failure.  Individuals with FA 
should be followed by a Hematologist.  HLA-typing of siblings and parents should be performed 
in preparation for BMT.  Also, assessment of liver and kidney function, iron levels and blood 
counts should be measured regularly, as well as bone marrow aspiration annually to evaluate cell 
morphology and to identify cytogenetic abnormalities.  When an individual has bone marrow 
failure, androgen administration can help the blood counts, but responses may be transient and 
side effects can be problematic.  Ultimately, bone marrow transplantation is warranted.  
Hematopoietic stem cell transplantation is the only curative therapy for the hematological 
manifestations of FA. Since individuals with FA are exquisitely sensitive to the toxicity of the 
usual chemotherapy and radiation regimens used in preparation for BMT, reduced doses are 
typically used.  There are limitations to BMT.   It is often difficult to find a donor and the 
procedure has about a 25% mortality rate due to graft versus host disease and infections as a 
result of immunosuppression.  Also, patients remain at risk for solid tumor development.   
There are also management issues to consider regarding cancer prevention and treatment.  
FA individuals should avoid toxic agents associated with tumorigenesis, and radiographic studies 
should be minimized, as these exposures are known to cause DNA damage.  Additional cancer 
surveillance is also warranted.  Recommendations include annual rectal examinations, frequent 
dental and oropharyngeal examinations, annual esophageal endoscopy may be considered, 
females should have an annual gynecological examination with pap smears, and prompt and 
aggressive workup for any symptoms suggestive of a malignancy should be pursued.   Treatment 
of malignancies is challenging as a result of the increased toxicity associated with chemotherapy 
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 and radiation therapy in individuals with FA.  Treatment with decreased doses or modified 
regimens at experienced centers may be possible.  
Molecular aspects of Fanconi anemia 
1.1.6. Molecular Pathogenesis 
Eight FANC proteins (A/B/C/F/G/I/J/L) assemble in a nuclear complex and two other 
proteins, FANCD1/BRCA2 and FANCD2 act downstream of the core complex. The products of 
six cloned FA genes (A, C, D2, E, F, G) are orphan proteins with little or no homology to each 
other or to other known proteins. FANCG is identical to the human XRCC9 gene, which was 
identified in a screen for genes that could correct chromosomal instability following DNA 
damage in Chinese hamster UV40 cells (23).  The FANCD2 protein has lower eukaryote 
homologues — in Drosophila, Arabidopsis, and C. elegans (42).  Recent evidence supports a 
model whereby the proteins of seven cloned FA genes interact in a common cellular pathway. 
The gene for FANCD1 was recently identified as the tumor suppressor/breast cancer 
susceptibility gene, BRCA2 (9).  FANCD1/BRCA2 is not required for FANCD2 
monoubiquitination, but is still required for resistance to crosslinking agents like mitomycin C 
(MMC) or diepoxybutane (DEB). Recently, FANCL, was identified as the E3 ligase required for 
FANCD2 monoubiquitination (17).  FANCD2 is also phosphorylated by the ataxia-telangiectasia 
kinase, ATM, in a process that regulates a radiation-induced cell cycle checkpoint (41). The FA-I 
and FA-J complementation groups have recently been described, though the genes have yet to be 
identified [49]. 
At least six of the FA proteins (A, C, E, F, G, and L) are assembled in a nuclear complex.  
This FA protein complex is required for the monoubiquitination of the FANCD2 protein in 
response to DNA damage (Figure 2).  The FANCD2 protein has two functions: 1) it is 
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 monoubiquitinated in response to DNA crosslink damage leading to its interaction with BRCA2 
and function in DNA damage repair and 2) it is also phosphorylated by ATM, leading to the 
activation of an S phase checkpoint response.  FANCD2 has two forms: FANCD2-S (short form) 
and FANCD2-L (long form).  In response to DNA damage, this complex monoubiquitinates the 
FANCD2 protein promoting its translocation to BRCA1 repair foci.  Ubiquitination of FANCD2 
converts it from the –S to the –L form and activates the protein (8).     
Disruption of this pathway leads to the common cellular and clinical abnormalities 
observed in FA [9]. The FA genes and their products associate to form a pathway that interacts 
with several DNA damage response proteins involved in cell cycle checkpoints or DNA damage 
repair.  These are thought to include BLM, ATM, BRCA1/2, XPF, and the 
MRE11/RAD50/NBS1 complex.  The precise function of this interaction is still unknown.  
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 1.1.7. Fanconi repair pathway 
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Figure 2: FA genes in response to DNA damage 
In response to DNA damage, the Fanconi D2 (FANCD2) protein is monoubiquitinated the Fanconi L protein in a 
process requiring the core complex containing Fanconi proteins A, C, E, F, G, and L. Following monoubiquitination, 
FANCD2 associates with the tumor suppressor proteins BRCA1 and BRCA2/FANCD1 where it promotes DNA 
repair. ATM-dependent FANCD2 phosphorylation plays a role in radiation-induced cell cycle arrest.  (Modified 
from 8) 
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 FA is diagnosed by sensitivity to interstrand crosslink (ICL) damage.  Crosslinking 
agents are DNA damaging drugs that join opposite strands of the DNA double helix and form 
covalent bridges known as ICLs.  ICLs prevent strand separation and effect transcription and 
replication.  Both strands of DNA are affected. Therefore, there is no undamaged strand present 
to act as a template during repair of the DNA damage.  ICL repair is thought to be very complex 
and proteins from different repair pathways are utilized to cope with the ICLs including NER 
(nucleotide excision repair), TCR (transcription-coupled repair), and mismatch repair pathways.  
The exact mechanism by which ICL repair occurs is unknown, although it has been suggested 
that ICL repair takes place during S phase of the cell cycle (27).  If there is an ICL, the 
replication fork stalls resulting in the formation of a DSB.  The ICL must be excised, likely by 
the NER-endonuclease ERCC1-XPF before the replication-induced DSB can be repaired and 
replication continues (29). The Fanconi pathway is activated in response to certain kinds of DNA 
damaging agents that cause double-strand breaks in DNA, such as crosslinking agents.   In FA 
cells that are unable to repair ICL-induced, replication-dependent DSBs, chromosome breaks 
may be rejoined by nonhomologous end-joining (NHEJ).  This can result in correct rejoining of a 
chromosome, or incorrect joining of different broken chromosomes, leading to chromosome 
translocations that can lead to quadriradial formation, triradials and other chromosomal 
aberrations indicative of error-prone DSB repair (dicentrics, giants, chromosome gaps).  In the 
absence of NHEJ, chromatid breaks accumulate and persist, without rejoining in aberrant 
structures.   
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 Summary 
Squamous cell carcinoma of the head and neck has not been identified as part of an inherited 
cancer syndrome.  This specific cancer has been mostly attributed to environmental factors, such 
as tobacco and alcohol use.  However, it is possible that HNSCC cases may be explained by 
genetic factors.    Knowledge of the high incidence of HNSCC in individuals diagnosed with 
Fanconi anemia, leads to the possibility that individuals diagnosed with HNSCC may have 
defects in the FA genes.  Also, because of the complexity of diagnosing FA, it is possible that 
atypical (young, non-smokers, non-drinkers) patients who develop HNSCC may have Fanconi 
anemia.  Finally, the increasing knowledge of the molecular aspects of DNA damage repair 
pathways could lead to a better understanding of the development of cancer and in patients with 
HNSCC as well as improve FA diagnosis.   
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 2. Hypothesis 
Head and neck squamous cell carcinoma cell lines exhibit defects in the Fanconi anemia pathway 
for DNA damage repair. 
3. Specific Aims 
1. To determine if head and neck cancer cell lines exhibit an increased susceptibility to 
chromosome breakage and radial formation upon exposure to DNA crosslinking agents, as 
occurs in  Fanconi anemia cells. 
2. To determine if head and neck cancer cells are deficient in the damage response to DNA 
interstrand crosslinks by testing for the presence of FANCD2 ubiquitination in the presence of 
DEB. 
3. To compare the molecular results with clinical information about the patients corresponding to 
cell lines to determine if there is a possible susceptibility to head and neck and related cancers 
because of a deficient DNA damage response pathway.  
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 4. Materials and Methods 
 
 
Patient Cell Lines 
Cell lines derived from tumors of consenting patients who had surgical removal of a head and 
neck squamous cell carcinoma between April 1994 and October 1995 were utilized and given an 
identification number.  These include: UPCI:SCC078, UPCI:SCC084, UPCI:SCC116, 
UPCI:SCC122, UPCI:SCC125, UPCI:SCC131, UPCI:SCC136, and UPCI:SCC142.  Table 3 
summarizes the known clinical information about these patients.   Two Fanconi anemia cell lines 
(SV40-transformed dermal fibroblasts) from the NIGMS Coriell Cell Repository were used.  
This included a cell line form a patient with genotype FANCA-/- (GM06914) and a cell line 
from a patient with genotype FANCD2-/- (GM16633).  Control peripheral blood from a 
anonymous normal male <age 40 with no family history of FA was obtained in June 2004.  
Table 3 Summary of clinical characteristics, personal and family information from patients whose tumors 
were examined 
Cell line 
UPCI:SCC 
Sex Age at 
diagnosis 
Risk 
Factors 
Family history of cancer Primary cancer 
078 M 60 Alcohol 
Worked in 
Mill 
Brother-Colon Ca, Prostate 
Father-Throat 
 
Retromolar trigone 
084 M 52 Tobacco 
Alcohol 
None Retromolar trigone 
116 M 57 Tobacco 
Alcohol 
Worked in coal 
mine 
Father- Prostate Alveolar 
Ridge 
122 M 63 Tobacco 
Alcohol 
None Tongue 
125 F 78 Tobacco None Alveolar 
Ridge 
131 M 73 Tobacco 
Alcohol 
Worked in coal 
mine 
None FOM 
136 F 64 Tobacco None Floor of Mouth 
142 M 58 Tobacco 
Alcohol 
None Tonsil 
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Cell Culture 
Cells were cultured in MEM medium (Invitrogen, Gaithersburg, MD) with 10% fetal bovine 
serum (Irvine Scientific, Santa Ana, CA) and antibiotics as described previously by Shuster et 
al., [2000]. Once established, two T-25 flasks per cell line were used for experimentation.    The 
protocol for testing peripheral blood samples for chromosome aberrations was adapted from the 
described method in the AGT Cytogenetics Manual (1). Fifty nanograms  
 of DEB was added to one of the flasks of each cell line and the corresponding flask of each of 
the cell lines was used as a control.  The flasks were incubated at 37ºC for 48 hours and 
harvested for cytogenetic studies following exposure to 50 µg Colcemid™ (Irvine Scientific, 
Santa Ana, CA) for 4.5 hours. After removal from flasks, cells were treated with a hypotonic 
0.075M KCl solution for 18 min at 37°C, then fixed with a 3:1 methanol:acetic acid fixative for 
20 min at room temperature. Cells were washed two more times in this fixative, and fixed cell 
pellets were stored at -20°C prior to use.  Slides were made and solid stained according to the 
conventional Geimsa staining method (AGT Cytogenetics manual pg. 264).  Metaphase spreads 
on the slides were analyzed and the aberrations were scored.   
 
Scoring of chromosome aberrations 
Slides made from each cell line were coded and scored by two separate individuals. These 
individuals were unaware of which cell line they were looking at and whether it was treated with 
DEB.   Each individual analyzed 50 metaphase spreads from 50 different cells in each cell line, 
treated and untreated. A standard cytogenetic scoring sheet was used to tally chromosome 
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 aberrations. Aberrations that were scored as a single break include: chromatid breaks/gaps, 
minutes, dots, and fragments and aberrations that were scored as two breaks included: triradials, 
quadriradials, dicentrics, giants, and chromosome breaks.  Results were presented as average 
number of breaks per chromosome and adjusted for anueploidy of the tumor cell lines.  Cell lines 
with >1 break/chromosome were categorized as having increased breakage and those with <0.5 
breaks/chromosome were considered normal as per the standard scoring method used in the AGT 
manual.   
 
Statistical Analysis 
After the results from the blinded breakage analysis was completed, the Wilcoxon rank sum test 
was done to compare the overall mean of chromosome aberrations between cases and controls.  
This test is used to compare two groups that are not normally distributed.  This test showed the 
effect the DEB treatment had on the cell lines and their ability to repair breaks and were graphed 
to reflect this comparison.   
A calculation of baseline genomic instability was done to compare the average breaks per 
chromosome in the untreated cell lines to the average breaks per chromosome in the untreated 
control peripheral blood. 
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Immunoblots 
Cell Lysates 
Each cell line was grown to 70-80% confluence in two T-75 flasks as described above.  Of the 
two flasks for each of the cell lines, one flask from each cell line was treated with 50ng of DEB 
and the other was not treated and used as a control.  The cells were scraped from the flask and 
centrifuged to make cell pellets and centrifuged.  The cell pellets were washed three times with 
PBS and centrifuged to remove supernatant and transferred to eppendorf tubes and washed with 
PBS.  Cells were microcentrifuged  to remove any debris in the supernatant.  The supernatant 
was then removed and then suspended in lysis buffer (see reagents below) for 20 min on ice 
followed by centrifugation at 4oC for 15 min.  Protein concentrations were measured on a 
spectrophotometer using Bradfords reagent using 10ul of cell lysate + 200ul of Bradford reagent 
+ 800 ul of deionized water.  Protein concentrations were equalized to 1ug/ul and 12-20ul of 
loading dye was added.  Samples were set in boiling water for 5 min and stored in the freezer at  
-20oC  for further use. 
. 
Gel Preparation  
A 7% polyacrylamide running gel was made as outlined below and polymerized for 
approximately 20 minutes.  The stacking gel (preparation outlined below) was then poured on 
top of the running gel, to accomodate a comb.  The comb was then removed, 1X SDS 
electrophoresis buffer was poured into the apparatus.  The wells of the apparatus were filled with 
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 the sample and dye and a protein marker loaded in one of them.  Samples were run for 
approximately 90 minutes at 120V to observe migration of bands.  The blots were then 
transferred to polyvinylidene fluoride (PVDF) microporous membrane (Millipore), which was 
pretreated with methanol and transfer buffer.  Blots were then stained with amido black to detect 
total protein and then destained with methanol. 
 
RUNNING GEL STACKING GEL 
Distilled water 7.6 ml Distilled water 3ml 
Tris pH 8.8 (1.5M) 3.75ml Tris pH 6.8 (0.5M) 1.25ml 
30% acryl, 8% BA 3.5ml 30% acryl, 8% BA 650ul 
10% SDS 150ul 10% SDS 50ul 
10% APS 80ul 10% APS 35ul 
Temed 14ul Temed 7ul 
 
 
 
 
Probing with antibodies 
 
Blots were washed with three changes of TBST (see reagents below) three times over 5-15 min. 
Membranes were blocked with 15 ml of 5% milk solution (powdered nonfat dry milk) in TBST 
and allowed to rock at room temperature for 1 -1.5 hours.  Blots were again washed with three 
changes of TBST three times for 5 min.  Primary antibody-mouse monoclonal FANCD2 (FI-17; 
Santa Cruz Biotech) was added to a staining dish at room temperature and allowed to rock 
overnight.  The primary antibody was removed and the blots were washed with three changes of 
TBST three times at 5-10 minutes.  The secondary antibody, rabbit anti-mouse IgG-HRP at a 
concentration of 1/3000 was added with 5% milk solution to the staining dish and allowed to 
rock for 1.5 hours. The secondary antibody was removed and then washed again with three 
changes of TBST, three times for 5 min each.  Western blot chemiluminescence reagents (500ul 
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 each) were added and developed in the dark at room temperature on film  (Blue Sensitive 
Medical Research Grade X-Ray Film, LPS, Inc.). 
Reagents: 
 
Resolving buffer (1.5M) 
72.6gms of Tris base in 400 ml of distilled water. Adjust pH to 8.8 
Make sure that initially you dissolve the tris base in 350 ml of d/w as at least 35-50 ml of 
HCl will be used to bring the pH to 8.8. 
 
Stacking Buffer (0.5M) 
Dissolve 6 grams of Tris base in 100 ml of distilled water. Adjust pH to 6.8. 
 
10% SDS 
Dissolve 10 grams of SDS in 100 ml of distilled water. 
 
10% APS 
Dissolve 1 gm of APS in 10 ml of distilled water. 
 
1X SDS Electrophoresis buffer. 
Sr No Reagent Amount 
   
1 Tris base 3.05 
grams 
2 Glycine 14.4 
grams 
3 SDS 1 gm 
4 Distilled water 1.0 L 
 
1X Transfer buffer 
Sr No Reagent Amount  
    
1 Tris base 18.2 
grams 
4.55g 
2 Glycine 86.5 
grams 
21.63g 
3 Methanol 400 ml 100ml 
4 Distilled water 4.0 L 1.0L 
!!! Always add methanol at the end. 
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 1X TBST 
Sr No Reagent Amount 
   
1 Tris base 6.05 
grams 
2 NaCl 14.6 
grams 
3 HCl 2.8 ml 
4 Tween 20 1.0  ml 
5 Distilled water 2.0 L 
 
 1X Sample Buffer 
Sr No Reagent Amount 
   
1 Stacking buffer 2.5 ml 
2 10% SDS 4.0 ml 
3 Glycerol 2.0 ml 
4 Beta mercaptoethanol 1.0  ml 
5 Distilled water 0.5 ml 
    Total  10.0 ml 
 
Lysis Buffer 
Sr No Reagent Amount 
   
1 1 M Tris base pH .4 5.0 ml 
2 5 M NaCl 15.0 ml 
3 0.5M EDTA 5.0 ml 
4 Triton x100 1% 
Store at 4oC. 
 
Protease inhibitor 
Sr No Reagent Amount 
   
1 Ethanol 1 ml 
2 aprotinine 5.0 mg 
3 leupeptine 10.0 mg 
Protease inhibitor (2) 
Sr No Reagent Amount 
   
1 Lysis Buffer 1 ml 
2 Pepstatin 4ml 
3 Leupeptine 40ml 
4 DTT 5ml 
5 PMSF 5ml 
Good for one day.  Thaw DTT and PMSF completely in water bath before using. 
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 Leupeptin 
Dissolve to 10mg/ml in dH2O. 
Pepstatin 
Dissolve to 10mg/ml in dH2O. 
DTT (1M) 
Boil in dH2O. 
PMSF (100mM) 
Dissolve in isopropanol. 
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5.  Results 
Chromosome Breakage 
Eleven total cell lines were examined to compare the effect of the cross-linking agent, DEB, on 
DNA damage repair.  Cells with a competent DNA damage response, specifically in the FANC 
pathway, should not express increased chromosome breakage when exposed to this agent.  
Figure 3 shows the average number of breaks per chromosome in each cell line, comparing those 
treated with DEB to matched untreated controls.  Both FANCA-/- and FANCD2-/- cell lines 
show the largest induction of breakage after exposure to DEB.  UPCI:SCC125, UPCI:SCC131, 
and UPCI:SCC142 all show significant increased breakage (>1.0 breaks per chromosome).  
UPCI:SCC084, UPCI:SCC122, and UPCI:SCC136 show moderate breakage (0.5> breaks per 
chromosome <1.0).  Human peripheral blood lymphocytes (HPBL) cells show an increase in 
breaks in the treated cell lines compared to controls, but still fall within the normal breakage 
range (<0.5 breaks per chromosome).  UPCI:SCC078 has slightly higher breakage in the 
untreated cells than in the treated, indicating spontaneous genomic instability.  SCC116 also has 
slightly higher breakage in the untreated cells than in the treated, but also has a much higher 
level of breakage in the untreated cells when compared to the other cell lines.  The percent of 
cells with radial formation was also calculated.  The FANCD2-/- cell line had 10% of cells with 
radial formation and the FANCA-/- cell line had 36% of cells with radial formation when 
exposed to DEB.  Only UPCI:SCC142 showed radial formation in response to DEB and this was 
observed in 3% of cells. 
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 The baseline, or spontaneous rate of genomic instability in these cells lines was determined by 
comparing the mean number of breaks per chromosome in the untreated cell lines to the 
untreated peripheral blood lymphocytes.  UPCI:SCC084 had a lower number of breaks in the 
untreated cell line when compared to untreated HPBL.  All of the other cell lines showed 
increased breakage and therefore, more genomic instability in the untreated cell lines compared 
to HPBL, with UPCI:SCC116 having the highest number of chromosome breaks when untreated.   
Comparison of Chromosome Breaks in cell lines 
treated with DEB (D) versus untreated (C)
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Figure 3: Average chromosome breaks in treated versus untreated HNSCC cell lines 
Note that FANCA and FANCD2 have the highest induction of breakage when treated with DEB 
(D).  All other cell lines show an increase in breakage except UPCI:SCC078 and UPCI:SCC116. 
 
 
Types of aberrations were tallied in each cell line for both treated and untreated and 
results are shown in Table 4.  Note that there are several aberrations that involve two 
chromosome breaks indicated by formation of rings, dicentrics, giants, chromosome breaks and 
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 radials.  In these cell lines the most frequent aberrations observed are minutes and dots.  Only 
UPCI:SCC142  and FANCA and FANCD2 showed radial formation. 
Overall induction of breakage in treated and 
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Figure 4: Overall increase in breakage in cell lines after DEB treatment 
The FANC cell lines and UPCI:SCC084 and UPCI:SCC125 had the largest induction of 
breakage after treatment with DEB.  This suggests that these cell lines have the greatest 
sensitivity to crosslinking agents. 
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Table 4: Summary of frequency of the types of chromosome aberrations  
 
Cell line Chromosome BreaksChromatid BreaksRadials Giant Ring Minutes Dot DicentricFragment
HPBL control 0 11 0 4 0 5 2 0 1 
HPBL treated 7 4 0 3 0 23 5 0 1 
078 control 0 4 0 1 1 4 1 0 0 
078 DEB 0 11 1 4 0 5 2 0 1 
084 control 0 3 0 0 0 1 4 1 0 
084 DEB 5 4 0 0 1 38 8 0 17 
116 control 4 23 0 6 2 34 7 8 4 
116 DEB 63 48 0 5 2 20 14 1 22 
122 control 3 11 0 0 0 18 1 1 4 
122 DEB 11 15 0 8 0 45 4 2 2 
125 control 2 6 0 2 1 2 7 1 0 
125 DEB 19 23 0 8 9 22 30 27 0 
131 control 5 11 0 1 0 16 3 4 4 
131 DEB 5 34 0 0 2 36 33 1 11 
136 control 4 4 0 7 0 16 6 1 8 
136 DEB 2 13 0 4 10 12 12 8 4 
142 control 8 25 0 0 1 33 19 8 5 
142 DEB 39 85 4 7 2 27 8 5 3 
FANCD2 control 1 6 0 3 1 15 8 7 4 
FANCD2 DEB 35 62 16 9 2 15 7 5 13 
FANCA control 9 15 0 5 0 9 18 10 2 
FANCA DEB 74 80 52 25 7 14 17 14 12 
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 Baseline genomic instability
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Figure 5: Baseline genomic instability in cell lines compared to HPBL 
Not that UPCI:SCC116 had the highest rate of spontaneous instability, FANCA, FANCD2, 
andUPCI:SCC142 also have a high rate of genomic instability, and all other UPCI:SCC’s have 
spontaneous instability except for UPCI:SCC084 when compared to the spontaneous instability 
in the human peripheral blood lymphocyte cells (HPBL).  
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Figure 5: Chromosome Breakage 
Select metaphase spreads comparing chromosome 
breakage in the presence of DEB.  (5A) Control 
peripheral blood lymphocytes do 5B)  FANCD2-/- cell 
line has increased chromosome breakage and a defective 
DNA damage response in the presence of a cross-linking 
agent.  Arrows not have any chromosome breakage and 
therefore have a normal DNA damage response in the 
presence of a cross-linking agent.  (show radial 
formation and single and double-strand breaks.  (5C) 
Cell line SCC142 in response to DEB.  There is 
increased breakage, but it is not as severe as in the FA 
cells. Arrow shows fused chromosomes as a result of 
breakage. 
B
C 
A 
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 Western Blots 
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Figure 6: Western Blots for FANCD2 
Immunoblotting was performed to assess the presence and ubiquitination of FANCD-2 protein in the UPCI:SCC cell 
lines.  Two FANC cell lines (FANCA-/- and FANCD2-/-) were used as negative controls. Cellular proteins were 
separated and probed with anti-FANCD2 antibody. These results are not conclusive, but interpretation is as follows: 
(A) FANCA-/- (GM06914) shows FANCD2 protein expression, but not ubiquitination of FANCD2.  FANCD2 -/- 
shows no expression of the FANCD2 protein. (B) shows a selection of SCC cell lines.  All show FANCD2 protein 
expression, and SCC078, SCC122, and SCC125 show ubiquitination of FANCD2.  (C) shows another selection of 
cell lines, all of which show FANCD2 protein expression.  None of these cell lines show ubiquitination of FANCD2. 
Arrows show the FANCD2 protein (FANCD2-S) and the ubiquitination (FANCD2-L).   
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 6. Summary of results in relation to 11q13 
Table 5 summarizes the results and the relationship to 11q13 status.  The  UPCI:SCC cell lines 
used for experimentation were chosen based on whether they have 11q13 amplification and/or 
distal loss of 11q.  Because several of the genes on distal 11q are involved in DNA damage 
repair and also may interact with the FANC pathway, we wanted to see if there was any 
correlation between 11q loss and defects in the FANC pathway.  
Table 5: Summary of results 
Cell Line 11q13 status Baseline 
Genomic 
Instability 
(compared to 
HPBL control) 
DEB induction 
(increased breaks 
per chromosome) 
Presence of 
FANCD2 
protein 
Ubiquitination 
of FANCD2 
FANCD2 Unknown 3.7 X increased High (>1.0) No No 
FANCA Unknown 5.6 X increased High (>1.0) Yes No 
SCC116 No gene 
amplification, 
No gene loss 
10.7 X 
increased 
None 
(treated>untreated) 
Yes No 
SCC122 No gene 
amplification, 
gene loss 
2.5 X increased Moderate 
(>0.5, <1.0) 
Yes Yes 
SCC125 No gene 
amplification, 
gene loss 
1.8 X increased High (>1.0) Yes Yes 
SCC142 No gene 
amplification, 
gene loss 
7.2 X increased High (>1.0) Yes No 
SCC078 Gene 
amplification, 
gene loss 
2.7 X increased None (<0.5) Yes Yes 
SCC084 Gene 
amplification, 
gene loss 
0.7 X increased High (>1.0) Yes No 
SCC131 Gene 
amplification, 
gene loss 
3.1 X increased High (>1.0) Yes No 
SCC 136 Gene 
amplification, 
gene loss 
3.7 X increased Moderate 
(>0.5, <1.0) 
Yes No 
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 7.  Discussion 
 
Eleven cell lines (summarized in Table 3) were examined to measure the DNA damage 
response to the crosslinking agent, DEB.  Cells with a competent DNA damage response, 
specifically in the FANC pathway , should not have increased chromosome breakage compared 
to normal human lymphocytes when exposed to this agent and are expected to show FANCD2 
ubiquitination by western blot.  Cell lines that show increased breakage in the presence of DEB 
may have a defect in the FANC pathway, which may correlate with lack of FANCD2 
ubiquitination.  Alternatively, FANCD2 may be ubiquitinated but not be fully functional, or there 
may be a mutant protein downstream of FANC (i.e. BRCA1), which results in an inability to 
repair the DNA damage, leading to increased chromosomal aberrations.  Figure 3 shows the 
average number of breaks per chromosome in each cell line comparing cells treated with DEB to 
those left untreated and figure 6 shows the western blots.  The UPCI:SCC cell lines were 
grouped according to their breakage status after treatment with DEB for analysis.  This method 
of grouping was chosen as breakage analysis is the “gold standard” in diagnosing FA.  
UPCI:SCC125, UPCI:SCC131, and UPCI:SCC142 all show DEB-induced breaks compared to 
normal cells, characterized by >1.0 breaks per chromosome.  UPCI:SCC084, UPCI:SCC122, and 
UPCI:SCC136 show moderate breakage, characterized as >0.5 breaks per chromosome <1.0.  
UPCI:SCC116 also shows moderate breakage, but has a very high rate of genomic instability.  
UPCI:SCC078 has a low level of breakage after treatment with DEB. Western blots were done to 
confirm the DNA damage response.  These results are inconclusive, but interpretation of the 
results are discussed. The specific results of each UPCI:SCC cell line and the controls are 
discussed below.   
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 As expected, both FANCA-/- and FANCD2-/- cell lines show the largest induction of 
breakage when treated with DEB.  FANCA-/- shows approximately six-fold increase in breakage 
with 36% of cells with radial formation FANCD2-/- shows approximately a four-fold increase in 
breakage with 10% of cells with radial formation, both in keeping with the formal diagnosis of 
Fanconi anemia.  Western blot supports these results, as FANCD2-/- does not show any 
FANCD2 protein expression and FANCA-/- shows the presence of FANCD2, but no 
ubiquitination.  The complete absence of FANCD2 protein results in no interaction with BRCA 
proteins to repair DNA damage, hence the increased DEB-induced breaks and radials in the null 
cell line.  In the absence of FANCA protein function, the FANC complex cannot activate 
FANCD2 and therefore results in undetectable levels of the ubiquitinated form of FANCD2 and 
deficient damage repair. 
  The group of UPCI:SCC cell lines that show the largest induction of breakage, are not 
similar in FANCD2 protein expression.  UPCI:SCC125 shows approximately a ten-fold increase 
in breakage (p<0.01), but no radial formation. By western blot analysis UPCI:SCC125 shows 
ubiquitination of FANCD2 in the presence of DEB.  This indicates that the FANC pathway is 
likely intact, and the breaks are a result of a defect downstream from the FA pathway.  This cell 
line is known to have distal chromosome 11q13 loss, so the loss of ATM, CHEK1, H2AX, and 
MRE11, which all play a role in DSB repair may contribute to the increased number breaks 
observed.  It should also be noted that UPCI:SCC125 is a very heterogeneous tumor cell line, as 
the percent of cells with loss are almost equal to the percent of cells without loss. Therefore, 
these results may reflect the specific cell population tested, and not that of the entire tumor.  It is 
possible that the cell population represented originated from a cell with distal 11q loss.     
UPCI:SCC131 shows approximately a three-fold increase in breakage (p< 0.01) and no radial 
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 formation.  UPCI:SCC131 does not show FANCD2 monoubiquitination in the presence of DEB.  
The FANCD2 protein is present, but its activity is unknown due to the lack of ubiquitination.  It 
is possible that the protein is non-functional.  This could mean that there could be a defect in any 
of the proteins in the FANC complex.  This cell line is known to have 11q13 amplification and 
loss.  Therefore, loss of distal 11q and possible haploinsufficiency of the genes could also 
contribute to the increased level of breakage via a defect in DSB repair.  UPCI:SCC142 shows 
approximately a two-fold increase in breakage (p<0.01) and 3% of cells with radial formation.  
UPCI:SCC142 also has a high level of breaks in the untreated cell line, indicating spontaneous 
genomic instability.  Western blot analysis of UPCI:SCC142 shows presence of the FANCD2 
protein, but no ubiquitination.  This suggests that like in UPCI:SCC131, the FANCD2 protein 
may be non-functional as a result of a defect in FANCD2 itself or a defect in the FANC complex 
that ubiquitinates FANCD2.  UPCI:SCC142 is known to have 11q loss, which also might 
contribute to defects in DNA damage repair.  Even though all of these cells lines show increased 
breakage similar to the amount of breakage seen in cells of an individual diagnosed with FA, the 
absence of significant radial formation suggests that the breakage is not a result of “classical” 
defects in the FANC pathway.  All of these cell lines also have distal 11q loss, but the 
ubiquitination results are not consistent.   Since UPCI:SCC125 shows FANCD2 ubiquitination, it 
is possible the tumor may  have already had a defect or acquired a mutation in one of the genes 
on distal 11q (i.e. MRE11) that acts downstream of the FANC pathway.  This results in breakage, 
but an intact FANC pathway.  In UPCI:SCC131 and UPCI:SCC142, it is appears that the 
breakage results from a defect upstream of the FANC pathway, resulting in no ubiquitination of 
FANCD2.    
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 The UPCI:SCC cell lines that show moderate breakage, are not consistent with defects in 
the FANC pathway. UPCI:SCC084 shows approximately a seven-fold increase in the number of 
cells with breaks (p<0.01) but no radial formation.  This cell line shows low spontaneous 
genomic instability, and a definite increase in breakage when exposed to DEB.  By western blot, 
there is not FANCD2 ubiquitination.  This suggests that breakage could have occurred as a result 
of a defect in the FANC complex or as a result of a defect upstream in the pathway.  
UPCI:SCC084 is known to have both 11q13 amplification and loss.  Loss of DNA damage 
response genes at this location could also contribute to the observed increased number of breaks 
UPCI:SCC122 shows approximately a two-fold increase in breakage (p< 0.01) and no radial 
formation.  Western blot analysis shows ubiquitination of FANCD2, which shows the FANC 
pathway is intact in this cell line.  The breaks may have result from a defect in DNA damage 
repair downstream of the FANC pathway.  Because this cell line has 11q loss, the loss of DNA 
damage repair genes, specifically MRE11, which participates in the repair DSBs, may be 
responsible for in the increased number of breaks without radial formation. UPCI:SCC136 shows 
less than a two-fold increase in breakage (p=0.08) and no radial formation.  Western blot 
analysis shows no ubiquitination of FANCD2.  This indicates that there may be defect elsewhere 
in the pathway that caused defective DNA damage repair, especially since the increase in 
breakage was not statistically significant in the presence of DEB.  The FANCD2 protein may not  
be activated because of defects elsewhere in the pathway.  UPCI:SCC136 is known to have 
11q13 amplification and distal loss, which may account for other defects in the pathway. 
UPCI:SCC078 has slightly higher breakage in the untreated cells than in the treated.  This 
increase in breakage was not statistically significant (p-value=0.59).  Since UPCI:SCC078 
untreated cell line showed a higher incidence of spontaneous breaks, this indicates that this 
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 particular cell line has baseline genomic instability that is increased when compared to other cell 
lines used, and breakage levels are not increased in the presence of a crosslinking agent.  
Western blot analysis of UPCI:SCC078 shows that in the presence of DEB, FANCD2 is 
ubiquitinated. This suggests that in UPCI:SCC078, the FANC pathway is intact and is able to 
repair damage caused by a crosslinking agent.  Therefore, there may be a defect elsewhere in the 
DNA damage response pathway that lead to tumor development.  UPCI:SCC078 is known to 
have 11q13 amplification and distal loss.  Loss of DNA damage repair genes at this location may 
explain the higher baseline genomic instability as well as well as the intact Fanconi pathway. 
UPCI:SCC116 also has slightly higher breakage in the untreated cells than in the treated 
cells, which is statistically significant (p< 0.01). This cell line also has a much higher level of 
breakage in the untreated cells when compared to the other cell lines.  Therefore, UPCI:SCC116 
cell line has a high rate of genomic instability and it is not increased in the presence of 
crosslinking agent.  Western blot confirms the presence of FANCD2, but does not show 
ubiquitination in the presence of DEB.  Even though FANCD2 can be detected by western blot, 
the protein function is unknown due to lack of ubiquitination.  It is possible that it is a non-
functional protein, or that there is a defect in the FANC complex that results in absence of 
ubiquitination of FANCD2.  SCC116 does not have 11q13 amplification or distal loss.  These 
results combined with the increased chromosome breakage/genomic instability in the untreated 
cell line suggest that there is a defect elsewhere in the DNA damage response and does not 
include the DNA damage repair genes on chromosome 11.   
HPBL cells show an increase in breaks in the treated cell lines compared to controls, but 
still fall within the normal breakage range (<0.5 breaks per chromosome).   
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 The results of this study show that head and neck tumor cell lines clearly exhibit defects 
in DNA damage response as illustrated by increased chromosome breakage in the presence of the 
DNA damaging agent, DEB.  However, the clinical diagnosis of Fanconi anemia is made only 
when there are >10% cells with radial formation as other syndromes (i.e. Nijmegen breakage 
syndrome (NBS)) will show increased breakage in the presence of a crosslinking agent.  Western 
blot analysis confirmed that the FANCD2 protein is present, but is not consistently 
ubiquitinated/activated in the cell lines.   It is unlikely that any of the patients whose tumors were 
used to derive the UPCI:SCC cell lines have/had FA.  This is expected, as these patients had 
environmental exposures associated with HNSCC (tobacco use, alcohol use, and job-related 
exposures) and their cancers were diagnosed at a later age.  These characteristics do not correlate 
with a hereditary predisposition to HNSCC or FA, in which early onset of HNSCC (<age 40) 
usually in the absence of environmental exposures is observed.  However, in the UPCI:SCC cell 
lines tested, the presence of increased spontaneous and DEB-induced breaks, as well as 
occasional defects in FANCD2 ubiquitination  is consistent with a defect in the FANC pathway 
specifically in the HNSCC tumor.  This could be a result of 1) two acquired mutations in the cell 
that eventually led to the tumor, 2) a single mutation in patients who are/were carriers 
(heterozygous) for FA mutations that also acquired a mutation or had somatic loss, 3) patients 
who have germline FA mutations, or 4) patients whose tumors are haploinsufficient for the 
FANC genes.  It is also possible that the increased breakage could have resulted from DNA 
damage response defects upstream or downstream in the repair pathway and that they play a role 
in the development of HNSCC.  However, the defects in the Fanconi pathway do not correlate 
with 11q13 amplification and/or loss patterns.  These results could possibly be confounded by 
the fact that cell lines can represent asynchronous cell populations due to clonal expansion and 
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 may only adequately represent part of the tumor.  Also, cells may not be dividing at the same rate 
and may not have been exposed to DEB at the same point in the cell cycle.  It is also possible 
that in the presence of DEB, cells may have undergone apoptosis and the cell population we 
tested was a fraction of the original cell population.  Finally, it is not completely understood as to 
how all of the DNA damage repair genes interact with each other, which makes it difficult to 
determine where the damage was not repaired.   
Therefore, further studies are warranted.  The other FANC proteins can be tested by 
western blot to determine defects in the core complex.  This could explain why many of the 
UPCI:SCC cell lines are not ubiquitinated in response to cross linking agents.   
Fluorescence in situ hybridization (FISH) of FANCD2 on chromosome 3p25.3 should be 
performed to determine copy number of the gene.  Many head and neck tumors also exhibit loss 
of 3p and therefore FANCD2 may be lost on one or more chromosomes leading to defects in 
DNA damage repair.  This test also can detect haploinsufficiency of FANCD2 in tumor cells.  
Cell lines with overall loss of FANCD2 might correlate with the cell lines already known to show 
defects in the FANC repair pathway such as those with increased breakage or those which are 
not ubiquitinated in response to DNA damage.   
 A functional assay for detection of BRCA foci should also be performed. When 
FANCD2 is ubiquitinated, it interacts with BRCA1.  BRCA1 forms nuclear foci in response to 
DNA damage.  Therefore, if the FA pathway is completely intact, nuclear focus formation would 
be expected in response to damage and functional FANCD2 will colocalize with these BRCA1 
foci.  This would confirm the possibility that the FANC pathway is intact in some cell lines and 
that the damage is not repaired as a result of defects somewhere downstream in the pathway.   
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 Study and correlation of other genes involved in DNA damage repair is also warranted.  
ATM and ATR are especially important to study as they are known to activate the FANC 
pathway.  Knowing if there are defects in those specific DNA damage repair genes could give 
more information about the apparent defects in the FA genes in the HNSCC cell lines.   
It also important to study the relationship between HNSCC and FA clinically.  Because 
of the rarity and variability of FA, it is often not diagnosed until the patient is diagnosed with 
cancer.   Therefore, FA should be considered in the case of an atypical clinical presentation of 
head and neck cancer and/or if other associated cancers are present (i.e. esophageal, cervical).  
Physicians should be suspicious of patients who present with HNSCC who are at a young age 
(<40), non-smokers, and non-drinkers. Because individuals with FA are hypersensitive to 
radiation and chemotherapy when crosslinking agents are used (such as Cisplatin), general 
adjuvant treatment for HNSCC would be extremely toxic and lethal to the patient.  A detailed 
family history should be obtained and genetic counseling for risks provided to family members. 
Currently, only mutation analysis can detect carriers/heterozygotes of FA.  BRCA2 
heterozygotes are at an increased risk to develop breast, ovarian, pancreatic, prostate, and skin 
cancers.  Because BRCA2 is an FA gene as well, it is possible that heterozygous carriers of 
mutations in the other FA genes (A, B, C, D2, etc.) could also have an increased risk for cancer.  
Further investigation might reveal the underlying defects in HNSCC as well as other cancers that 
are currently considered sporadic.   
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 Public Health Significance 
Head and neck cancer (including oral cancer) is expected to account for 11,000 deaths in 
the United States in 2005.  While this specific type of cancer is considered sporadic and strongly 
associated with tobacco and alcohol use, it is suspected that there are underlying genetic 
mechanisms that predispose individuals to head and neck cancer.  Otherwise, all individuals with 
these exposures would have the disease.  Examining the association between FA and HNSCC 
increases our understanding the genetic mechanisms that lead to head and neck cancer in the 
general population.  This has both clinical and scientific value.   
First, knowing that a patient has an underlying susceptibility to develop HNSCC can 
allow for more frequent HNSCC screening.  Currently, there are no recommended regular early 
detection programs that screen for HNSCC.  This results in many HNSCC being diagnosed at a 
later pathological stage where surgery may not be an option, or where chemotherapy and/or 
radiation may not be successful.  This in turn leads to the high mortality rate and low five-year 
survival rate for individuals diagnosed with HNSCC.  As discussed previously, survival rate is 
significantly increased when HNSCC is detected and treated at an early stage.  Development of 
screening programs, like the increased screening recommended in FA patients, would allow for 
earlier detection and increased survival as well as decreased morbidity.   
Treatment and management may also be different in a patient with an underlying genetic 
susceptibility for HNSCC.  Understanding the biological development of cancer could lead to 
better use of current treatments/therapies or could lead to the development of better treatments.  
In most patients diagnosed with HNSCC, adjuvant chemotherapy and radiation is given after 
surgery.  Individuals with FA are sensitive to radiation and hypersensitive to certain 
chemotherapeutic agents.  Therefore, patients with defects in DNA damage repair due to a 
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 mutation in the FA pathway might also have these sensitivities to treatment.  In contrast, if the 
FA pathway is specifically affected in HNSCC tumors, this offers the opportunity to specifically 
treat this class of tumors with chemotherapeutic agents that cause DNA interstrand crosslinks, as 
FA deficient cells will be hypersensitive to these agents. 
Individuals who have a mutation in the FA pathway and therefore DNA damage defects, 
may also have increased risk to develop other cancers.  Therefore, understanding the exact 
mechanisms that cause HNSCC as well as understanding the function of the FA genes could lead 
to a better understanding of the development of other types of cancers and their relationship to 
HNSCC.  Again, this understanding would lead to better risk assessment of cancer and therefore 
increased screening and earlier detection of specific cancers as well as use of safer therapies and 
reduced morbidity and mortality. 
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